$BRKR
BRUKER CORP

2020 Q4 Form 10-Q Financial Statement

#000110465920122498 Filed on November 06, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $627.5M $511.4M $521.1M
YoY Change 4.6% -1.86% 11.68%
Cost Of Revenue $314.5M $263.1M $267.2M
YoY Change 3.59% -1.53% 9.51%
Gross Profit $313.0M $248.3M $253.9M
YoY Change 5.64% -2.21% 14.06%
Gross Profit Margin 49.88% 48.55% 48.72%
Selling, General & Admin $131.5M $114.6M $125.3M
YoY Change -0.68% -8.54% 17.65%
% of Gross Profit 42.01% 46.15% 49.35%
Research & Development $57.10M $48.30M $46.10M
YoY Change 22.27% 4.77% 10.29%
% of Gross Profit 18.24% 19.45% 18.16%
Depreciation & Amortization $21.70M $20.50M $18.90M
YoY Change 18.58% 8.47% 18.87%
% of Gross Profit 6.93% 8.26% 7.44%
Operating Expenses $188.3M $167.1M $166.1M
YoY Change 6.14% 0.6% 8.21%
Operating Profit $124.7M $81.20M $87.80M
YoY Change 5.95% -7.52% 27.06%
Interest Expense -$5.800M -$5.700M -$4.700M
YoY Change 0.0% 21.28% 104.35%
% of Operating Profit -4.65% -7.02% -5.35%
Other Income/Expense, Net -$1.300M -$5.900M -$4.600M
YoY Change 85.71% 28.26% 24.32%
Pretax Income $105.7M $75.30M $83.20M
YoY Change -4.95% -9.5% 27.22%
Income Tax $34.40M $20.00M $21.70M
% Of Pretax Income 32.54% 26.56% 26.08%
Net Earnings $68.90M $54.30M $61.30M
YoY Change 0.44% -11.42% 41.24%
Net Earnings / Revenue 10.98% 10.62% 11.76%
Basic Earnings Per Share $0.35 $0.40
Diluted Earnings Per Share $447.4K $0.35 $0.39
COMMON SHARES
Basic Shares Outstanding 153.1M 153.2M 154.2M
Diluted Shares Outstanding 154.3M 155.6M

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $731.8M $617.1M $302.4M
YoY Change 6.85% 104.07% 11.96%
Cash & Equivalents $681.8M $567.1M $296.3M
Short-Term Investments $50.00M $50.00M $6.100M
Other Short-Term Assets $165.6M $183.2M $186.1M
YoY Change -3.72% -1.56% 24.56%
Inventory $692.3M $695.9M $586.7M
Prepaid Expenses
Receivables $335.3M $329.9M $358.8M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.925B $1.826B $1.434B
YoY Change 7.16% 27.34% 13.67%
LONG-TERM ASSETS
Property, Plant & Equipment $395.5M $354.6M $278.1M
YoY Change 29.21% 27.51% 6.59%
Goodwill $320.4M $312.8M $282.3M
YoY Change 9.35% 10.8%
Intangibles $229.1M
YoY Change -1.76%
Long-Term Investments
YoY Change
Other Assets $39.60M
YoY Change 135.71%
Total Long-Term Assets $1.124B $1.053B $918.1M
YoY Change 15.26% 14.73% 46.29%
TOTAL ASSETS
Total Short-Term Assets $1.925B $1.826B $1.434B
Total Long-Term Assets $1.124B $1.053B $918.1M
Total Assets $3.049B $2.879B $2.352B
YoY Change 10.01% 22.42% 24.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $134.6M $113.9M $116.6M
YoY Change 13.68% -2.32% 16.6%
Accrued Expenses $20.40M
YoY Change
Deferred Revenue $189.2M $126.1M
YoY Change 37.2%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.200M $1.700M $300.0K
YoY Change 340.0% 466.67% -98.05%
Total Short-Term Liabilities $791.9M $683.2M $643.0M
YoY Change 22.66% 6.25% 14.19%
LONG-TERM LIABILITIES
Long-Term Debt $842.3M $828.2M $518.5M
YoY Change 3.63% 59.73% 130.24%
Other Long-Term Liabilities $176.1M $363.2M $264.3M
YoY Change 54.61% 37.42% -4.1%
Total Long-Term Liabilities $1.018B $1.191B $782.8M
YoY Change 9.9% 52.2% 56.31%
TOTAL LIABILITIES
Total Short-Term Liabilities $791.9M $683.2M $643.0M
Total Long-Term Liabilities $1.018B $1.191B $782.8M
Total Liabilities $1.810B $1.875B $1.426B
YoY Change 15.14% 31.48% 32.98%
SHAREHOLDERS EQUITY
Retained Earnings $1.407B
YoY Change 10.34%
Common Stock $216.3M
YoY Change 8.31%
Preferred Stock
YoY Change
Treasury Stock (at cost) $667.0M $598.8M $543.8M
YoY Change 22.66% 10.11%
Treasury Stock Shares $22.06M $20.69M $19.35M
Shareholders Equity $961.2M $952.1M $845.2M
YoY Change
Total Liabilities & Shareholders Equity $3.049B $2.879B $2.352B
YoY Change 10.01% 22.42% 24.51%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income $68.90M $54.30M $61.30M
YoY Change 0.44% -11.42% 41.24%
Depreciation, Depletion And Amortization $21.70M $20.50M $18.90M
YoY Change 18.58% 8.47% 18.87%
Cash From Operating Activities $203.0M $82.40M $52.40M
YoY Change 49.05% 57.25% 90.55%
INVESTING ACTIVITIES
Capital Expenditures -$28.80M -$17.60M -$16.20M
YoY Change 2.13% 8.64% 42.11%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$30.60M $3.600M
YoY Change -100.0% -950.0% -120.34%
Cash From Investing Activities -$28.80M -$48.20M -$12.60M
YoY Change -26.53% 282.54% -56.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -74.30M -225.5M -19.50M
YoY Change -126.74% 1056.41% -233.56%
NET CHANGE
Cash From Operating Activities 203.0M 82.40M 52.40M
Cash From Investing Activities -28.80M -48.20M -12.60M
Cash From Financing Activities -74.30M -225.5M -19.50M
Net Change In Cash 99.90M -191.3M 20.30M
YoY Change -73.35% -1042.36% 56.15%
FREE CASH FLOW
Cash From Operating Activities $203.0M $82.40M $52.40M
Capital Expenditures -$28.80M -$17.60M -$16.20M
Free Cash Flow $231.8M $100.0M $68.60M
YoY Change 41.0% 45.77% 76.35%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
60700000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
65600000
CY2020Q3 brkr Intangibles And Other Long Term Assets Noncurrent
IntangiblesAndOtherLongTermAssetsNoncurrent
325200000
CY2019Q4 brkr Intangibles And Other Long Term Assets Noncurrent
IntangiblesAndOtherLongTermAssetsNoncurrent
310500000
CY2020Q3 us-gaap Assets
Assets
2879400000
CY2019Q4 us-gaap Assets
Assets
2771500000
CY2020Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
1700000
CY2019Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
500000
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Entity Central Index Key
EntityCentralIndexKey
0001109354
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-30833
dei Entity Registrant Name
EntityRegistrantName
BRUKER CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3110160
dei Entity Address Address Line1
EntityAddressAddressLine1
40 Manning Road
dei Entity Address City Or Town
EntityAddressCityOrTown
Billerica
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01821
dei City Area Code
CityAreaCode
978
dei Local Phone Number
LocalPhoneNumber
663-3660
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value per share
dei Trading Symbol
TradingSymbol
BRKR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
153108102
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
567100000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
678300000
CY2020Q3 us-gaap Short Term Investments
ShortTermInvestments
50000000.0
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
6600000
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
329900000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
362200000
CY2020Q3 us-gaap Inventory Net
InventoryNet
695900000
CY2019Q4 us-gaap Inventory Net
InventoryNet
577200000
CY2020Q3 us-gaap Other Assets Current
OtherAssetsCurrent
183200000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
172000000.0
CY2020Q3 us-gaap Assets Current
AssetsCurrent
1826100000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
1796300000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
354600000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
306100000
CY2020Q3 us-gaap Goodwill
Goodwill
312800000
CY2019Q4 us-gaap Goodwill
Goodwill
293000000.0
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
113900000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
118400000
CY2020Q3 us-gaap Deferred Income Current
DeferredIncomeCurrent
154600000
CY2019Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
137900000
CY2020Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
413000000.0
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
388800000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
683200000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
645600000
CY2020Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
828200000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
812800000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
42100000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
47000000.0
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
363200000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
327900000
CY2019Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
21100000
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
260000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
260000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
173872664
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
173502375
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
153184527
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
154155798
CY2020Q3 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
1700000
CY2019Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
1700000
CY2020Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
20688137
CY2019Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
19346577
CY2020Q3 us-gaap Treasury Stock Value
TreasuryStockValue
598800000
CY2019Q4 us-gaap Treasury Stock Value
TreasuryStockValue
543800000
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5200000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-25500000
CY2020Q3 brkr Other Shareholders Equity
OtherShareholdersEquity
1554400000
CY2019Q4 brkr Other Shareholders Equity
OtherShareholdersEquity
1474400000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
952100000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
906800000
CY2020Q3 us-gaap Minority Interest
MinorityInterest
10600000
CY2019Q4 us-gaap Minority Interest
MinorityInterest
10300000
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
962700000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
917100000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2879400000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2771500000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
511400000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
521100000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1360000000.0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1472700000
CY2020Q3 us-gaap Cost Of Revenue
CostOfRevenue
263100000
CY2019Q3 us-gaap Cost Of Revenue
CostOfRevenue
267200000
us-gaap Cost Of Revenue
CostOfRevenue
733200000
us-gaap Cost Of Revenue
CostOfRevenue
773700000
CY2020Q3 us-gaap Gross Profit
GrossProfit
248300000
CY2019Q3 us-gaap Gross Profit
GrossProfit
253900000
us-gaap Gross Profit
GrossProfit
626800000
us-gaap Gross Profit
GrossProfit
699000000.0
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
114600000
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
125300000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
338200000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
369900000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48300000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46100000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
140900000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
141000000.0
CY2020Q3 us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
4200000
CY2019Q3 us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
-5300000
us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
12200000
us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
4900000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
167100000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
166100000
us-gaap Operating Expenses
OperatingExpenses
491300000
us-gaap Operating Expenses
OperatingExpenses
515800000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
81200000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
87800000
us-gaap Operating Income Loss
OperatingIncomeLoss
135500000
us-gaap Operating Income Loss
OperatingIncomeLoss
183200000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5900000
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4600000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-15400000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-14000000.0
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
75300000
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
83200000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
120100000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
169200000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20000000.0
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
21700000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
30000000.0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
40000000.0
CY2020Q3 us-gaap Profit Loss
ProfitLoss
55300000
CY2019Q3 us-gaap Profit Loss
ProfitLoss
61500000
us-gaap Profit Loss
ProfitLoss
90100000
us-gaap Profit Loss
ProfitLoss
129200000
CY2020Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
1000000.0
CY2019Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
200000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
1200000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2800000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
600000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
54300000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
61300000
us-gaap Net Income Loss
NetIncomeLoss
88900000
us-gaap Net Income Loss
NetIncomeLoss
128600000
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.35
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.58
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.83
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.35
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.82
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
153200000
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
154200000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
153700000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
155700000
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
154300000
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
155600000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
154800000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
157000000.0
CY2020Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
64000000.0
CY2019Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
26100000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
110100000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
92000000.0
CY2020Q3 us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
1400000
CY2019Q3 us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
200000
us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
1500000
us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
1000000.0
CY2019Q3 us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
-1200000
us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
-500000
us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
-1800000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
62600000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
27100000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
109100000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
92800000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
917100000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
700000
CY2020Q1 brkr Stock Issued During Period Value Restricted Stock Units Vested
StockIssuedDuringPeriodValueRestrictedStockUnitsVested
-100000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3000000.0
CY2020Q1 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.04
CY2020Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
7400000
CY2020Q1 brkr Acquisition Of Hain Lifescience
AcquisitionOfHainLifescience
1300000
CY2020Q1 brkr Net Income Loss Including Portion Attributable To Redeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest
-10600000
CY2020Q1 brkr Other Comprehensive Income Loss Net Of Tax Excluding Redeemable Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxExcludingRedeemableNoncontrollingInterest
2000000.0
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
924600000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1300000
CY2020Q2 brkr Stock Issued During Period Value Restricted Stock Units Vested
StockIssuedDuringPeriodValueRestrictedStockUnitsVested
-100000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-500000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-25500000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-6400000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-111300000
CY2020Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
50000000.0
CY2020Q2 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.04
CY2020Q2 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
6100000
CY2020Q2 brkr Net Income Loss Including Portion Attributable To Redeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest
-24200000
CY2020Q2 brkr Other Comprehensive Income Loss Net Of Tax Excluding Redeemable Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxExcludingRedeemableNoncontrollingInterest
9900000
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
906600000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
500000
CY2020Q3 brkr Stock Issued During Period Value Restricted Stock Units Vested
StockIssuedDuringPeriodValueRestrictedStockUnitsVested
-1200000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4100000
CY2020Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
5000000.0
CY2020Q3 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.04
CY2020Q3 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
6300000
CY2020Q3 brkr Net Income Loss Including Portion Attributable To Redeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest
-55300000
CY2020Q3 brkr Other Comprehensive Income Loss Net Of Tax Excluding Redeemable Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxExcludingRedeemableNoncontrollingInterest
8700000
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
962700000
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
905100000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3100000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2700000
CY2019Q1 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.04
CY2019Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
6300000
CY2019Q1 brkr Net Income Loss Including Portion Attributable To Redeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest
-30900000
CY2019Q1 brkr Other Comprehensive Income Loss Net Of Tax Excluding Redeemable Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxExcludingRedeemableNoncontrollingInterest
-13900000
CY2019Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
921600000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2700000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2600000
CY2019Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
100000000.0
CY2019Q2 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.04
CY2019Q2 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
6300000
CY2019Q2 brkr Net Income Loss Including Portion Attributable To Redeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest
-37300000
CY2019Q2 brkr Other Comprehensive Income Loss Net Of Tax Excluding Redeemable Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxExcludingRedeemableNoncontrollingInterest
12200000
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
870100000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3100000
CY2019Q3 brkr Stock Issued During Period Value Restricted Stock Units Vested
StockIssuedDuringPeriodValueRestrictedStockUnitsVested
-800000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3500000
CY2019Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
42300000
CY2019Q3 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.04
CY2019Q3 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
6200000
CY2019Q3 brkr Net Income Loss Including Portion Attributable To Redeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest
-61700000
CY2019Q3 brkr Other Comprehensive Income Loss Net Of Tax Excluding Redeemable Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxExcludingRedeemableNoncontrollingInterest
-34400000
CY2019Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
854700000
us-gaap Profit Loss
ProfitLoss
90100000
us-gaap Profit Loss
ProfitLoss
129200000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
58700000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
57300000
us-gaap Share Based Compensation
ShareBasedCompensation
10900000
us-gaap Share Based Compensation
ShareBasedCompensation
10100000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
500000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
129200000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
77200000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1700000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-36900000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8000000.0
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
109700000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
80900000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-15300000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
10300000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-9100000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-6400000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
20100000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
9700000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
32400000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-9100000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
11800000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
36200000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
100000000.0
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
6400000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
56100000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
58800000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
79000000.0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
68400000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
44800000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
100000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
11000000.0
us-gaap Payments For Proceeds From Hedge Investing Activities
PaymentsForProceedsFromHedgeInvestingActivities
-7100000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-163900000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-119200000
us-gaap Maturities Of Senior Debt
MaturitiesOfSeniorDebt
15000000.0
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
305100000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
50500000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
297500000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
250600000
us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
400000
us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
4800000
us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
400000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
100000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1100000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8100000
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
6200000
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
5600000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
54400000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
142300000
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
18500000
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
18800000
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
1200000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-87300000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22100000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10700000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
511400000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
521100000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-26300000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
681900000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
326300000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
570600000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
300000000.0
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3600000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3900000
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3500000
CY2019Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3700000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BRUKER CORPORATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2020</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><b style="font-weight:bold;">1.</b>    <b style="font-weight:bold;">Description of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="background-color:#ffffff;">Bruker Corporation, together with its consolidated subsidiaries (Bruker or the Company), develops, manufactures and distributes high-performance scientific instruments and analytical and diagnostic solutions that enable its customers to explore life and materials at microscopic, molecular and cellular levels. Many of the Company’s products are used to detect, measure and visualize structural characteristics of chemical, biological and industrial material samples. The Company’s products address the rapidly evolving needs of a diverse array of customers in life science research, pharmaceuticals, biotechnology, applied markets, cell biology, clinical research, microbiology, in-vitro diagnostics, nanotechnology and materials science research.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background-color:#ffffff;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:12.8pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company has four operating segments, <i style="font-style:italic;">Bruker BioSpin Group, Bruker CALID Group, Bruker Scientific Instruments (BSI) Nano Segment </i>and <i style="font-style:italic;">Bruker Energy &amp; Supercon Technologies (BEST)</i>. The Company has three reportable segments, <i style="font-style:italic;">BSI Life Science Segment, BSI NANO Segment</i> and <i style="font-style:italic;">BEST</i>.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:12.8pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:12.8pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:12.8pt;text-align:justify;text-indent:18pt;margin:0pt;">For financial reporting purposes, the Bruker BioSpin Group and Bruker CALID Group operating segments are aggregated into the reportable BSI Life Science Segment because each has similar economic characteristics, production processes, service offerings, types and classes of customers, methods of distribution and regulatory environments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background-color:#ffffff;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><i style="font-style:italic;">Bruker BioSpin</i> — The Bruker BioSpin Group designs, manufactures and distributes enabling life science tools based on magnetic resonance technology. Bruker BioSpin Group’s revenues are generated by academic and government research customers, pharmaceutical and biotechnology companies and nonprofit laboratories, as well as chemical, food and beverage, clinical and other industrial companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><i style="font-style:italic;">Bruker CALID (Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection) </i>- The Bruker CALID Group designs, manufactures and distributes life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies and radiological/nuclear detectors for Chemical, Biological, Radiological, Nuclear and Explosive (CBRNE) detection. Customers of the Bruker CALID Group include: academic institutions and medical schools; pharmaceutical, biotechnology and diagnostics companies; contract research organizations; nonprofit and  for-profit forensics laboratories; agriculture, food and beverage safety laboratories; environmental and clinical microbiology laboratories; hospitals and government departments and agencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The BSI NANO Segment designs, manufactures and distributes advanced X-ray instruments; atomic force microscopy instrumentation; advanced fluorescence optical microscopy instruments; analytical tools for electron microscopes and X-ray metrology; defect-detection equipment for semiconductor process control; handheld, portable and mobile X-ray fluorescence spectrometry instruments; and spark optical emission spectroscopy systems. Customers of the BSI NANO Segment include academic institutions, governmental customers, nanotechnology companies, semiconductor companies, raw material manufacturers, industrial companies, biotechnology and pharmaceutical companies and other businesses involved in materials analysis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The BEST reportable segment develops and manufactures superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare and "big science" research. The segment focuses on metallic low temperature superconductors for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research and other applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The unaudited condensed consolidated financial statements represent the consolidated accounts of the Company. All intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements as of September 30, 2020 and December 31, 2019, and for the three and nine months ended September 30, 2020 and 2019, have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) for Quarterly Reports on Form 10-Q and Article 10 of Regulation S-X. Accordingly, the financial information presented herein does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair statement have been included. The results for interim periods are not necessarily indicative of the results expected for any other interim period or the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">At September 30, 2020, the Company's significant accounting policies and estimates, which are detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, have not changed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Risks &amp; Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company is subject to risks common to its industry including, but not limited to, global economic conditions, government and academic funding levels, the impact of the COVID-19 pandemic, rapid technological change, changes in commodity prices, spending patterns of its customers, protection of its intellectual property, availability of key raw materials and components, compliance with existing and future regulation by government agencies and fluctuations in foreign currency exchange rates and interest rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In December 2019, a novel strain of coronavirus, referred to as COVID-19, surfaced in Wuhan, China. In March 2020, the COVID-19 outbreak was declared a pandemic by the World Health Organization. The virus has spread to over 200 countries and territories and continues to spread globally, including in the United States. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Impacts to the Company's business include temporary closures of many of the Company’s government and university customers and suppliers, disruptions or restrictions on employees' and customers' ability to travel, and delays in product installations to and from affected countries. In an effort to halt the outbreak of COVID-19, a number of countries, including the United States, have implemented and continue to implement significant restrictions on travel, shelter in place or stay at home orders, and business closures. Certain jurisdictions, including many within the United States, have begun implementing policies with the goal of re-opening these markets only to return to restrictions in the face of increases in new COVID-19 cases. For example, a number of states, including California, Massachusetts and New Jersey where the Company has significant operations, had issued shelter in place or stay-at-home orders. Although these states have begun implementing phased re-opening policies, many of the Company’s employees in these areas continue to work remotely, and any re-openings may be delayed or pulled back if the virus continues to spread. In addition, a number of the Company's production facilities had to either temporarily close or operate on a reduced capacity. Most commercial activity in sales and marketing, and customer demonstrations and applications training, are either being conducted remotely or postponed. Customer purchasing departments are operating at reduced capacity, and many customers could delay or cut capital expenditures and operating budgets. Even where customers have re-opened their sites, many still operate at productivity levels that are below pre-pandemic levels in an effort to accommodate safety protocols. The resurgence of the virus in Europe and North America may require the Company or its customers to close or partially close operations once again. These travel restrictions, business closures and reduction in operations at Bruker, customers, distributors, and/or suppliers have and will continue to adversely impact the Company's operations worldwide, including the ability to manufacture, sell or distribute products, as well as cause temporary closures of foreign distributors, or the facilities of suppliers or customers. This disruption of the Company's employees, distributors, suppliers and customers has and will continue to impact the Company’s global sales and future operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company is continuing to monitor and assess the effects of the COVID-19 pandemic on commercial operations, including its continued impact on revenue for the remainder of 2020. However, the Company cannot at this time accurately predict what effects these conditions will ultimately have on its  operations due to uncertainties relating to the severity of the disease, the duration of the outbreak, including the impact of any “second wave” of the virus, and the length or severity of the travel restrictions, business closures, and other safety and precautionary measures imposed by the governments of impacted countries. The pandemic has also adversely affected the economies and financial markets of many countries, which has affected and likely will continue to affect demand for the Company’s products and its operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The preparation of the  unaudited condensed consolidated financial statements requires the Company to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis the Company evaluates estimates, judgments and methodologies. Changes in estimates are recorded in the period in which they become known. The Company bases estimates on historical experience and on various other assumptions that they believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will directly or indirectly impact the business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, as well as the economic impact on local, regional, national and international customers and markets. The Company has made estimates of the impact of COVID-19 within the financial statements and there may be changes to those estimates in future periods. Actual results may differ from management's estimates if these results differ from historical experience.</p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
4
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1360000000.0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1472700000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
511400000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
521100000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1360000000.0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1472700000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
511400000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
521100000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1360000000.0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1472700000
CY2020Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
1910200000
CY2020Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
1910200000
CY2020Q3 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.62
CY2020Q3 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.62
CY2020Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2020Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
48200000
CY2019Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
43900000
CY2020Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
371700000
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
312500000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
180100000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4100000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
154800000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
157000000.0
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
155600000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8700000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3500000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9900000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4100000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3500000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9900000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8700000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0023
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0155
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y1M20D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y3M29D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.34
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.30
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0037
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0038
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
0
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
0
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
54300000
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
61300000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
88900000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
128600000
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
153200000
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
154200000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
153700000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
155700000
CY2020Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1100000
CY2019Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1400000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1100000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1300000
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
154300000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.83
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.35
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.58
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.35
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.82
CY2020Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
205100000
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
188800000
CY2020Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
261700000
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
206400000
CY2020Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
139100000
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
104500000
CY2020Q3 us-gaap Other Inventory Demo
OtherInventoryDemo
90000000.0
CY2019Q4 us-gaap Other Inventory Demo
OtherInventoryDemo
77500000
CY2020Q3 us-gaap Inventory Net
InventoryNet
695900000
CY2019Q4 us-gaap Inventory Net
InventoryNet
577200000
CY2020Q3 us-gaap Other Inventory In Transit
OtherInventoryInTransit
52700000
CY2019Q4 us-gaap Other Inventory In Transit
OtherInventoryInTransit
36000000.0
CY2019Q4 us-gaap Goodwill
Goodwill
293000000.0
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
13300000
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
6500000
CY2020Q3 us-gaap Goodwill
Goodwill
312800000
CY2020Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
474100000
CY2020Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
243100000
CY2020Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
231000000.0
CY2019Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
456600000
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
223400000
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
233200000
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
9000000.0
CY2019Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
9200000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
26700000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
29200000
CY2020Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
2500000
CY2019Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
2600000
CY2020Q3 us-gaap Long Term Debt
LongTermDebt
829900000
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
813300000
CY2020Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
1700000
CY2019Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
500000
CY2020Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
828200000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
812800000
CY2020Q3 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
741600000
CY2020Q3 brkr Line Of Credit Facility Maximum Borrowing Capacity Uncommitted By Leaders
LineOfCreditFacilityMaximumBorrowingCapacityUncommittedByLeaders
115400000
CY2020Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
141800000
CY2020Q3 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
715200000
CY2020Q3 brkr Cross Currency Swap Interest Effect
CrossCurrencySwapInterestEffect
1400000
brkr Cross Currency Swap Interest Effect
CrossCurrencySwapInterestEffect
5800000
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-22100000
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-22400000
CY2020Q3 us-gaap Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
-26600000
CY2019Q4 us-gaap Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
-6500000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20000000.0
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
21700000
CY2020Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.266
CY2019Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.261
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
30000000.0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
40000000.0
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.250
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.236
CY2020Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
19900000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
15900000
CY2020Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
1100000
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
400000
CY2019Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
100000
CY2020Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
100000
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
400000
us-gaap Restructuring Charges
RestructuringCharges
5700000
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
100000
us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.029
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019Q2 us-gaap Loss Contingency Damages Awarded Value
LossContingencyDamagesAwardedValue
20000
CY2020Q3 us-gaap Loss Contingency Damages Awarded Value
LossContingencyDamagesAwardedValue
11000
CY2020Q4 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
97700000
CY2016Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.04
brkr Common Stock Dividends Per Share Annual Target
CommonStockDividendsPerShareAnnualTarget
0.16
CY2020Q3 us-gaap Profit Loss
ProfitLoss
55300000
CY2019Q3 us-gaap Profit Loss
ProfitLoss
61500000
us-gaap Profit Loss
ProfitLoss
90100000
us-gaap Profit Loss
ProfitLoss
129200000
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
8600000
CY2019Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-36500000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
5100000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-38900000
CY2020Q3 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-100000
CY2019Q3 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-1100000
us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-14900000
us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-1700000
CY2020Q3 brkr Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest And Redeemable Noncontrolling Interest
ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAndRedeemableNoncontrollingInterest
64000000.0
CY2019Q3 brkr Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest And Redeemable Noncontrolling Interest
ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAndRedeemableNoncontrollingInterest
26100000
brkr Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest And Redeemable Noncontrolling Interest
ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAndRedeemableNoncontrollingInterest
110100000
brkr Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest And Redeemable Noncontrolling Interest
ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAndRedeemableNoncontrollingInterest
92000000.0
CY2020Q3 us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
1400000
CY2019Q3 us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
200000
us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
1500000
us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
1000000.0
CY2019Q3 us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
-1200000
us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
-500000
us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
-1800000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
62600000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
27100000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
109100000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
92800000
us-gaap Restructuring Charges
RestructuringCharges
-1400000
us-gaap Gain Loss On Sale Of Properties
GainLossOnSaleOfProperties
7800000
CY2019Q3 us-gaap Gain Loss On Sale Of Properties
GainLossOnSaleOfProperties
7800000
CY2020Q3 us-gaap Information Technology And Data Processing
InformationTechnologyAndDataProcessing
500000
CY2019Q3 us-gaap Information Technology And Data Processing
InformationTechnologyAndDataProcessing
800000
us-gaap Information Technology And Data Processing
InformationTechnologyAndDataProcessing
1800000
us-gaap Information Technology And Data Processing
InformationTechnologyAndDataProcessing
2800000
CY2020Q3 us-gaap Professional Fees
ProfessionalFees
300000
us-gaap Professional Fees
ProfessionalFees
4800000
CY2020Q3 brkr Restructuring Charges Excluding Cost Of Sales
RestructuringChargesExcludingCostOfSales
1700000
CY2019Q3 brkr Restructuring Charges Excluding Cost Of Sales
RestructuringChargesExcludingCostOfSales
-7400000
brkr Restructuring Charges Excluding Cost Of Sales
RestructuringChargesExcludingCostOfSales
4400000
brkr Restructuring Charges Excluding Cost Of Sales
RestructuringChargesExcludingCostOfSales
-5500000
CY2020Q3 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
900000
CY2019Q3 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
900000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
-1000000.0
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
5900000
CY2020Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
700000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1900000
CY2020Q3 brkr Other Miscellaneous Nonrecurring Expense
OtherMiscellaneousNonrecurringExpense
100000
CY2019Q3 brkr Other Miscellaneous Nonrecurring Expense
OtherMiscellaneousNonrecurringExpense
400000
brkr Other Miscellaneous Nonrecurring Expense
OtherMiscellaneousNonrecurringExpense
300000
brkr Other Miscellaneous Nonrecurring Expense
OtherMiscellaneousNonrecurringExpense
1700000
CY2020Q3 us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
4200000
CY2019Q3 us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
-5300000
us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
12200000
us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
4900000
CY2020Q3 us-gaap Restructuring Charges
RestructuringCharges
1900000
CY2019Q3 us-gaap Restructuring Charges
RestructuringCharges
-6800000
CY2019Q4 us-gaap Restructuring Reserve
RestructuringReserve
4600000
us-gaap Restructuring Charges
RestructuringCharges
5700000
us-gaap Payments For Restructuring
PaymentsForRestructuring
5700000
us-gaap Restructuring Reserve Translation And Other Adjustment
RestructuringReserveTranslationAndOtherAdjustment
-1000000.0
CY2020Q3 us-gaap Restructuring Reserve
RestructuringReserve
3600000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
511400000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
521100000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1360000000.0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1472700000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
81200000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
87800000
us-gaap Operating Income Loss
OperatingIncomeLoss
135500000
us-gaap Operating Income Loss
OperatingIncomeLoss
183200000
CY2020Q3 us-gaap Assets
Assets
2879400000
CY2019Q4 us-gaap Assets
Assets
2771500000

Files In Submission

Name View Source Status
0001104659-20-122498-index-headers.html Edgar Link pending
0001104659-20-122498-index.html Edgar Link pending
0001104659-20-122498.txt Edgar Link pending
0001104659-20-122498-xbrl.zip Edgar Link pending
brkr-20200930.xsd Edgar Link pending
brkr-20200930x10q.htm Edgar Link pending
brkr-20200930x10q_htm.xml Edgar Link completed
brkr-20200930xex31d1.htm Edgar Link pending
brkr-20200930xex31d2.htm Edgar Link pending
brkr-20200930xex32d1.htm Edgar Link pending
brkr-20200930_cal.xml Edgar Link unprocessable
brkr-20200930_def.xml Edgar Link unprocessable
brkr-20200930_lab.xml Edgar Link unprocessable
brkr-20200930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending